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Anti-inﬂammatoryAbstract In an attempt to ﬁnd out new, potent and safe anti-inﬂammatory molecules and as a con-
tribution in the chemistry of triterpenes, a series of 18b-glycyrrhetinic acid (GTA) derivatives (4a–j,
5a–e, 7–9, 11–13) were synthesized and evaluated as anti-inﬂammatory agents using carrageenan
induced rat paw edema method. The synthesized derivatives proved superior anti-inﬂammatory
activity to GTA. Moreover, some of the produced derivatives demonstrated higher effect than pred-
nisolone and indomethacin. This remarkable anti-inﬂammatory effect was combined with no detri-
mental effect on the gastrointestinal tract (GIT) of the test rats. All of the synthesized compounds
were characterized by NMR spectroscopy and high-resolution ESI mass spectrometry.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Typically possessing low toxicity and a broad spectrum of bio-
logical activities, plant triterpenoids are valuable raw materials
for the creation of new drugs (Schopke and Hiller, 1990;
Tolstikov et al., 1998; Platonov et al., 1995; Shon et al.,
1998). Glycyrrhizic (GZA) and glycyrrhetinic acid (GTA), as
well as their derivatives, exhibit a various biological effects,
including anti-inﬂammatory and anti-ulcer activity (Tolstikovet al., 1997, 1998; Platonov et al., 1995; Shon et al., 1998).
Consequently, they serve as pronounced starting materials
for effective anti-inﬂammatory, anti-allergic and antiulcer
preparations (Finney and Tarnoky, 1960; Gheorghiu et al.,
1971; Yano et al., 1989). GZA, GTA and their derivatives af-
fect the arachidonic acid cycle similar to the non-steroidal
anti-inﬂammatory agents (Inoue et al., 1988). In vitro research
has also demonstrated that GZA inhibits cyclooxygenase
activity and prostaglandin formation (speciﬁcally prostaglan-
din E2) (Ohuchi et al., 1981; Okimasu et al., 1983; Ohuchi
and Tsurufuji, 1982). Moreover, GZA and GTA are known
to inhibit phospholipase A2 activity, an enzyme critical to
numerous inﬂammatory processes (Kase et al., 1998).
Recently, some derivatives of GTA have shown their
inhibitory activity against interleukin-1b (IL-1b)-induced
prostaglandin E2 (PGE2) (Tsukahara et al., 2005). Also,
GZA inhibits reactive oxygen species (ROS) generation by
neutrophils. GZA signiﬁcantly decreases neutrophil-generated
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thought that one of GZA anti-inﬂammatory effects is attrib-
uted to this effect (Akamatsu et al., 1991; Wang and Nixon,
2001).
Some of GTA derivatives inhibited nitric oxide (NO) gener-
ation and suppressed superoxide anion formation by rat neu-
trophils; they also inhibited xanthine oxidase activity. These
actions may have value in the therapeutical treatment or pre-
vention of certain central as well as peripheral inﬂammatory
diseases associated with the increase of (NO) production
(Maitraie et al., 2009). Although being anti-inﬂammatory mol-
ecule, GTA is characterized by being anti-ulcer agent at the
same time. Its anti-ulcer effect is attributed to the sequential
inhibition of 15-hydroxyprostaglandin dehydrogenase and
D13-ketoprostaglandin reductase; the two enzymes are in-
volved in the gastric prostaglandin metabolism (Aly et al.,
2005). Prostaglandins promote healing of ulcers by stimulating
mucous secretion and cell proliferation in the stomach. Thus,
the local increase of prostaglandin concentration by glycyrrh-
etinic-derived compounds, promotes healing of ulcers.
GTA produces an undesired aldosterone-like effect
(Ulmann et al., 1975), potentiates the action of aldosterone
(Ishikawa and Saito, 1980), and inhibits its metabolism. At
the same time, GTA derivatives frequently exhibit a more pro-
nounced therapeutic action than does the initial GTA and pro-
duce no aldosterone-like side effects Takahashi et al., 1980;
Shibata et al., 1987). Hence, we aimed to make new derivatives
that exceed GTA activity with a better safety proﬁle.2. Results and discussion
2.1. Chemistry
GTA was isolated from Glycyrrhiza glabra roots in our labora-
tory by an unpublished method. Its identity was conﬁrmed by
IR, m.p. [291–292 C, lit. 292–294 (Abubakirov and Yatsyn,
1959)] and mixed m.p. The target derivatives were synthesized
by modiﬁcation of the two main active functional groups of
GTA (20-COOH and 3-OH). For the synthesis of compounds
4 and 5 series, the hydroxyl group was protected by acetylation
(Murav’ev and Savchenko, 1979) and the carboxylic group was
activated by the preparation of acid chloride (3) using SOCl2
(Adanin and Khaletskii, 1967) .The addition of few drops of
dimethyl formamide (Ibrahim et al., 1995), to enhance the
reaction led to decrease in the overall yield of the acid chloride.
After puriﬁcation, the acid chloride produced was reacted with
some aryl, alicyclic, heterocyclic amines and aryl phenols to
give the corresponding amides (4a–j) and esters (5a–e), respec-
tively (Scheme 1). The acid chloride method resulted in a high
yield for the produced amides and esters. The mixed anhydride
of GTA was prepared by reacting GTA with ethylchlorofor-
mate in presence of triethylamine in dichloromethane, but it
resulted in a poor yield for the produced amides (20%).
Compound 4g was hydrolyzed by alcoholic KOH to pro-
duce compound 6. The free –OH of the latter compound was
esteriﬁed with each of succinic and phthalic anhydrides using
excess amounts of both of them in presence of dry pyridine
and molecular sieve 4A to afford compounds 7 and 8, respec-
tively (Tsukahara et al., 2005). Compound 9 was prepared
through further amidation of compound 4g with p-toluidine
via mixed anhydride formation (Scheme 2).Methyl glycyrrhetate (10) was prepared by Fischer esteriﬁ-
cation of GTA with methanol; compounds 11–13 were pre-
pared through the reaction of (10) with excess succinic,
phthalic and maleic anhydrides, respectively in pyridine
(Kondratenko et al., 2001) (Scheme 3). During the reaction
with succinic and maleic anhydrides, reaction mixture got
dark. It grows faster in case of maleic than succinic anhydride.
Pyridine induces a chemical reaction of some violence which
yields carbon dioxide and a black brittle residue (Rittenberg
and Ponticorvo, 1960). Acetone was used during the working
up to dissolve this black brittle residue.
2.2. Biological activity
In the present investigation, variable synthesized compounds
were evaluated for their possible anti-inﬂammatory activity
in a rat model of carrageenan-induced paw edema, which is
a widely used animal model for determining the acute phase
of inﬂammation. The anti-inﬂammatory potency of the tested
compounds was compared with free GTA and two standard
drugs, prednisolone and indomethacin. Figs. 1 and 2 demon-
strate the potency of GTA and its synthesized derivatives ver-
sus prednisolone and indomethacin, respectively. It is
noteworthy to mention that the derivatives 4g, 4h, 5a and 11
showed greater anti-inﬂammatory potency than both prednis-
olone and indomethacin. However, compounds 4i, 8 and 9
showed almost the same anti-inﬂammatory potency of the ref-
erence standards. On the other hand, free GTA showed the
least potency as compared with the synthesized compounds.
At the end of the experiment, rats were killed under light
ether anesthesia by cervical dislocation; their stomachs were
excised, opened at the greater curvature and examined for
the presence of ulcers. All rat groups that received GTA, its
synthesized derivatives and prednisolone showed very few gas-
tric lesions or no ulcers at all, compared to rat groups that re-
ceived indomethacin, which showed some gastric ulcers with
considerable severity.
3. Materials and methods
Melting points were uncorrected and determined with electro-
therma capillary melting point apparatus. The NMR spectra
were measured on a Varian Unity 300 (300.145 MHz) and
on Buker AM-200 (200 MHz) spectrometers. ESI mass spectra
were recorded on a Finnigan LCQ spectrometer with quater-
nary pump Rheos 4000 (Flux Instrument). Flash chromatogra-
phy was carried out on silica gel (230–400 mesh). Rf values
were measured on Polygram SIL G/UV254 (Macherey–Nagel
& Co.). Reaction progress was followed and monitored using
thin layer chromatography (TLC, DF254) and eluted with the
following systems (a) benzene/ethyl acetate/AcOH (12:2:0.5)
or (b) hexane/ethyl acetate (6:4). Visualization was carried
out by either UV (254 nm, 365 nm) or spraying with metha-
nol/sulfuric acid (5%) and then heated with air dryer.
3.1. Isolation of GTA from Glycyrrhiza glabra roots
The dry powdered root of Glycyrrhiza glabra (1 kg) was trea-
ted with 5 L of 5% sulfuric acid. The mixture was reﬂuxed
for 6 h and left to cool. The mixture was ﬁltered off and the
residue was carefully washed with water and dried. The residue
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Scheme 1 Synthesis of amides and esters of GTA.
392 M.O. Radwan et al.was extracted by dry benzene in a soxhlet. The pale yellow ex-
tract was treated with 200 ml of acetic anhydride and the mix-
ture was reﬂuxed for 1 h, then it was left for 24 h at room
temperature. The reaction mixture was poured on crushed
ice, while stirring and the produced precipitate was ﬁltered
off and washed with water. The produced glycyrrhetinic acid
acetate (2) was crystallized several times from methanol to
produce colorless crystals [m.p. 315–317 C, lit. 317–318 C
(Murav’ev and Savchenko, 1979)]. Compound 2 was saponi-
ﬁed by reﬂuxing with 5% alcoholic NaOH for 3 h to liberate
free GTA (1).
3.2. Synthesis of the target derivatives
3.2.1. Glycyrrhetinic acid acetate (2), acetyl glycyrrhetyl
chloride (3) and methyl glycyrrhetate (10)
The three compounds were prepared according to published
methods (Murav’ev and Savchenko, 1979; Baltina et al., 1997).3.2.2. General procedures for the preparation of compounds 4a–j
and 5a–e
A solution of 3 (100 mg, 0.19 mmol) in dry benzene was added
drop wise to a stirred solution of the appropriate amine or phe-
nol (0.19 mmol) and triethylamine (27 ll, 0.19 mmol) in dry
benzene or THF. After complete addition, the mixture was
heated under reﬂux for 3 h and the course of reaction was
monitored using TLC. At the end of the reaction, water was
added; the mixture was washed with 2 N HCl (compounds
4a–j) or 2% NaOH (compounds 5a–e); benzene layer was sep-
arated, dried over anhydrous sodium sulfate and distilled off
under vacuum. The formed amide or ester was puriﬁed by ﬂash
column chromatography using the appropriate solvent system.
3.2.3. N-(phenethyl)-3b-acetyl-11-oxoolean-12-en-18b-H-30-
amide (4a)
M.p 121–123 C; yield 68%; (+)-ESI-MS: m/z (%)
638 ([M+ Na]+), 1254 ([2 M+ Na]+) 614 ([MH]);
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C40H57NO4Na);
1H NMR: d at 0.82 (s, 3H, CH3-28), 0.86 (s,
6H, CH3-23, 24), 1.07 (s, 3H, CH3-27), 1.12 (s, 3H, CH3-25),
1.25 (s, 3H, CH3-29), 1.34 (s, 3H, CH3-26), 2.01 (s, 3H,
CH3-32), 2.29 (s, 1H, CH-9), 2.78 (d, 1H, CH-1 eq), 2.85 (m,
2H, CH2-34), 3.52 (m, 2H, CH2-33), 4.47 (dd, 1H, CH-3),
5.45 (s, 1H, CH-12), 5.75 (t, 1H, NH), 7.22 (m, 5H, CH-20,
30, 40, 50, 60); 13C NMR: d at 38.74 (C-1), 23.68 (C-2), 80.56
(C-3), 37.97 (C-4), 54.95 (C-5), 17.30 (C-6), 32.61 (C-7),
45.28 (C-8), 61.64 (C-9), 36.86 (C-10), 199.85 (C-11), 128.33
(C-12), 169.09 (C-13), 43.52 (C-14), 26.34 (C-15), 26.31 (C-
16), 31.78 (C-17), 47.87 (C-18), 41.02 (C-19), 43.11 (C-20),
31.34 (C-21), 37.34 (C-22), 27.98 (C-23), 16.61 (C-24), 16. 34
(C-25), 18.59 (C-26), 23.48 (C-27), 28.36 (C-28), 29.95 (C-
29), 175.66 (C-30), 179.96 (C-31), 21.23 (C-32), 43.11 (C-33),
40.38 (C-34), 138.69 (C-10), 128.64 (C-20), 128.67 (C-30),
126.57 (C-40), 128.67 (C-50), 128.64 (C-60).3.2.4. N-(4-chlorophenyl)-3b-acetyl-11-oxoolean-12-en-18b-H-
30-amide (4b)
M.p 281–283 C; yield 82%; (+)-ESI-MS: m/z (%) 645
([M+ Na]+), 1267 ([2 M+ Na]+), 621 ([MH]);
(+)-HRESI-MS: m/z 623.3663 (calc: 623.3658 for
C38H53NO4Cl);
1H NMR: d at 0.83 (s, 3H, CH3-28), 0.88 (s,
6H, CH3-23, 24), 1.13 (s, 3H, CH3-27), 1.14 (s, 3H, CH3-25),
1.25 (s, 3H, CH3-29), 1.39 (s, 3H, CH3-26), 2.06 (s, 3H,
CH3-32), 2.37 (s, 1H, CH-9), 2.80 (d, 1H, CH-1 eq), 4.53
(dd, 1H, CH-3), 5.68 (1H, s, CH-12), 7.28 (d, 2H, CH-2’, 6’),
7.45 (d, 2H, CH-30, 50), 3 J (20, 30) = 3 J (50, 60) = 9 Hz; 13C
NMR: d at 38.77 (C-1), 23.52 (C-2), 80.57 (C-3), 38.01 (C-4),
54.99 (C-5), 17.34 (C-6), 32.68 (C-7), 45.37 (C-8), 61.76 (C-
9), 36.91 (C-10), 199.91 (C-11), 128.56 (C-12), 168.88 (C-13),
44.56 (C-14), 26.38 (C-15), 26.38 (C-16), 32.01 (C-17), 48.16
(C-18), 41.82 (C-19), 43.20 (C-20), 31.62 (C-21), 37.37 (C-
22), 28.02 (C-23), 16.66 (C-24), 16. 38 (C-25), 18.64 (C-26),
Scheme 3 Synthesis of esters of GTA.
Figure 1 Anti-inﬂammatory potency of GTA and its derivatives as compared with prednisolone.
394 M.O. Radwan et al.23.33 (C-27), 28.38 (C-28), 29.35 (C-29), 174.01 (C-30), 171.05
(C-31), 21.32 (C-32), 136.37 (C-10), 121.34 (C-20), 129.01 (C-30),
128.77 (C-40), 129.01 (C-50), 121.34 (C-60).
3.2.5. N-(benzyl)-3b-acetyl-11-oxoolean-12-en-18b-H-30-
amide (4c)
M.p 134–136 C; yield 67%; (+)-ESI-MS: m/z (%) 624
([M+ Na]+), 600 ([MH]); (+)-HRESI-MS: m/z 602.4203
(calc: 602.4203 for C39H56NO4);
1H NMR: d at 0.76 (s, 3H,
CH3-28), 0.82 (s, 6H, CH3-23, 24), 1.11 (s, 6H, CH3-27, 25),1.30 (s, 3H, CH3-29), 1.36 (s, 3H, CH3-26), 2.00 (s, 3H,
CH3-32), 2.28 (s, 1H, CH-9), 2.73 (d, 1H, CH-1 eq), 4.43 (s,
3H, CH3 and CH2-33), 5.51 (1H, s, CH-12), 5.91 (1H, s,
NH), 7.24 (6H, m, CH-20, 30, 40, 50, 60, CDCl3);
13C NMR: d
at 38.74 (C-1), 23.48 (C-2), 80.56 (C-3), 37.99 (C-4), 54.95
(C-5), 17.32 (C-6), 32.56 (C-7), 45.31 (C-8), 61.66 (C-9),
36.86 (C-10), 199.95 (C-11), 128.37 (C-12), 169.07 (C-13),
43.60 (C-14), 26.34 (C-15), 26.34 (C-16), 31.89 (C-17), 48.12
(C-18), 41.81 (C-19), 43.15 (C-20), 31.43 (C-21), 37.40 (C-
22), 28.00(C-23), 16.64 (C-24), 16. 35 (C-25), 18.63 (C-26),
Figure 2 Anti-inﬂammatory potency of GTA and its derivatives as compared with indomethacin.
Table 1 Anti-inﬂammatory potency of glycyrrhetic acid and some of its derivatives in comparison to prednisolone.
Compound Anti-inﬂammatory potency (%) Average potency in 4 h (%)
1 h 2 h 3 h 4 h
4g 153.3 131.7 130.9 139.1 138.8
4h 149.9 121.6 123.6 139.1 133.6
4i 111.5 105.8 94.2 94.8 101.6
5a 102.0 135.4 131.7 134.5 125.9
7 101.2 71.6 64.3 65.3 75.6
8 78.7 84.9 106.9 101.2 92.9
9 100.0 98.1 99.4 98.1 98.9
11 168.9 125.7 111.7 119.5 131.5
12 89.0 75.4 66.2 68.0 74.6
13 66.3 55.8 54.1 56.1 58.1
GTA 58.4 46.5 43.6 43.5 48.0
Prednisolone 100.0 100.0 100.0 100.0 100.0
Table 2 Anti-inﬂammatory potency of glycyrrhetic acid and some of its derivatives in comparison to indomethacin.
Compound Anti-inﬂammatory potency (%) Average potency in 4 h (%)
1 h 2 h 3 h 4 h
4g 96.6 131.0 131.4 139.1 124.5
4h 94.5 121.0 124.1 139.1 119.6
4i 70.3 105.2 94.6 94.8 91.2
5a 64.3 134.7 132.2 134.5 116.4
7 63.8 71.2 64.5 65.3 66.2
8 49.6 84.4 107.3 101.2 85.6
9 63.0 97.6 99.8 98.1 89.6
11 106.5 125.0 112.1 119.5 115.8
12 56.1 75.0 66.5 68.0 66.4
13 41.8 55.5 54.3 56.1 51.9
GTA 36.8 46.2 43.7 43.5 42.6
Indomethacin 100.0 100.0 100.0 100.0 100.0
Synthesis and biological activity of new 18b-glycyrrhetinic acid derivatives 39523.22 (C-27), 28.39 (C-28), 29.52 (C-29), 175.53 (C-30), 173.03
(C-31), 21.29 (C-32), 43.60 (C-33), 138.57 (C-10), 127.71 (C-20),
128.76 (C-30), 127.56 (C-40), 128.76 (C-50), 127.71 (C-60).
3.2.6. N-(3-chloro-4-Methylphenyl)-3b-acetyl-11-oxoolean-12-
en-18b-H-30-amide (4d)
M.p 167–169 C; yield 73%; (+)-ESI-MS: m/z (%) 658
([M +Na]+), 634([MH]); (+)-HRESI-MS: m/z 636.3800
(calc: 636.3814 for C39H55NO4Cl), 658.3620 (calc: 658.3634for C39H54NO4ClNa);
1H NMR: d at 0.81 (s, 3H, CH3-28),
0.87 (s, 6H, CH3-23, 24), 1.12 (s, 6H, CH3-27, 25), 1.24 (s,
3H, CH3-29), 1.37 (s, 3H, CH3-26), 2.05 (s, 3H, CH3-32),
2.29 (s, 3H, CH3-Ar), 2.36 (s, 1H, CH-9), 2.78 (d, 1H, CH-
1 eq), 4.52 (dd, 1H, CH-3), 5.69 (s, 1H, CH-12), 7.11 (m,
1H, CH-50), 7.29 (m, 1H, CH-60), 7.58 (s, 1H, CH-20), 7.71
(s, 1H, NH); 13C NMR: d at 38.72 (C-1), 23.44 (C-2), 80.54
(C-3), 37.96 (C-4), 54.91 (C-5), 17.29(C-6), 32.62 (C-7), 45.45
(C-8), 61.68 (C-9), 36.84 (C-10), 200.19 (C-11), 128.35
396 M.O. Radwan et al.(C-12), 169.55 (C-13), 43.21 (C-14), 26.32 (C-15), 26.32 (C-16),
31.94 (C-17), 48.26 (C-18), 41.47 (C-19), 43.21 (C-20), 31.51
(C-21), 37.33 (C-22), 27.99 (C-23), 16.63 (C-24), 16.31 (C-
25), 18.56 (C-26), 23.33 (C-27), 28.35 (C-28), 29.56 (C-29),
174.16 (C-30), 171.08 (C-31), 21.29 (C-32),136.83 (C-10),
118.31 (C-20), 134.35 (C-30), 130.84 (C-40), 131.68 (C-50),
120.64 (C-60), 20.22 (CH3- Ar).
3.2.7. N-(cyclohexyl)-3b-acetyl-11-oxoolean-12-en-18b-H-30-
amide (4e)
M.p 201–203 C; yield 77%; (+)-ESI-MS: m/z (%) 616
([M+ Na]+), 1210 ([2 M+Na]+); (+)-HRESI-MS: m/z
616.4333 (calc: 616.43362 for C38H59NO4Na);
1H NMR: d at
0.77 (s, 3H, CH3-28), 0.84 (s, 6H, CH3-23, 24), 1.09 (s, 3H,
CH3-27), 1.12 (s, 3H, CH3-25), 1.22 (s, 3H, CH3-29), 1.36 (s,
3H, CH3-26), 1.65 (m, 2H, CH2-d), 2.02 (s, 3H, CH3-32),
2.21 (m, 2H, CH-30, 50), 2.32 (s, 1H, CH-9), 2.76 (d, 1H,
CH-1 eq), 3.00 (m, 2H, CH-20, 60), 4.48 (dd, 1H, CH-3), 5.65
(s, 1H, CH-12), 3.78 (m, 1H, CH-10); 13C NMR: d at 38.58
(C-1), 23.49 (C-2), 80.55 (C-3), 37.84 (C-4), 54.82 (C-5),
17.35 (C-6), 32.52 (C-7), 45.32 (C-8), 61.70 (C-9), 36.75 (C-
10), 199.86 (C-11), 128.32 (C-12), 169.25 (C-13), 43.14 (C-
14), 26.28 (C-15), 26.28 (C-16), 31.72 (C-17), 48.08 (C-18),
41.83 (C-19), 43.14 (C-20), 31.35 (C-21), 37.26 (C-22), 27.85
(C-23), 16.45 (C-24), 16. 20 (C-25), 18.61 (C-26), 23.30 (C-
27), 28.50 (C-28), 28.51 (C-29), 174.51(C-30), 170.85 (C-31),
21.22 (C-32), 51.10 (C-10), 33.28 (C-20), 22.73 (C-30), 28.49
(C-40), 22.73 (C-50), 33.28 (C-60).
3.2.8. N-(4-Methylphenyl)-3b-acetyl-11-oxoolean-12-en-18b-
H-30-amide (4f)
M.p 181–183 C [lit. 180–182 C 9 Dalimov et al., 2001)]; yield
69%; (+)-ESI-MS: m/z (%) 624 ([M+ Na]+), 600 ([MH]-);
(+)-HRESI-MS: m/z 624.4021 (calc: 624.4023 for C39H55NO4-
Na); 1H NMR: d at 0.81 (s, 3H, CH3-28), 0.84 (s, 6H, CH3-23,
24), 1.14 (s, 3H, CH3-27), 1.16 (s, 3H, CH3-25), 1.24 (s, 3H,
CH3-29), 1.38 (s, 3H, CH3-26), 2.01 (s, 3H, CH3-32), 2.31 (s,
3H, CH3-Ar), 2.38 (s, 1H, CH-9), 2.79 (d, 1H, CH-1 eq),
4.52 (dd, 1H, CH-3), 5.64 (s, 1H, CH-12), 7.10 (d, 2H, CH-
30, 50), 7.38 (d, 2H, CH-20, 60), J20, 30 = J50, 60 = 6 Hz, 7.43 (s,
1H, NH); 1C NMR: d at 38.83 (C-1), 23.60 (C-2), 80.58 (C-
3), 38.06 (C-4), 55.02 (C-5), 17.43 (C-6), 32.74 (C-7), 45.41
(C-8), 61.75 (C-9), 36.97 (C-10), 199.74 (C-11), 128.39 (C-
12), 168.99 (C-13), 44.46 (C-14), 26.49 (C-15), 26.46 (C-16),
32.04 (C-17), 48.22 (C-18), 41.93 (C-19), 43.27 (C-20), 31.69
(C-21), 37.45 (C-22), 28.09 (C-23), 16.73 (C-24), 16. 43 (C-
25), 18.73 (C-26), 23.39 (C-27), 28.44 (C-28), 29.42 (C-29),
173.72 (C-30), 170.86 (C-31), 21.36 (C-32), 135.19 (C-10),
120.21 (C-20), 129.36(C-30), 133.87 (C-40), 129.36 (C-50),
120.21 (C-60), 20.88 (CH3- Ar).
3.2.9. N-(2-carboxyphenyl)-3b-acetyl-11-oxoolean-12-en-18b-
H-30-amide (4g)
M.p 174–176 C; yield 75%; (+)-ESI-MS: m/z (%) 654
([M+ Na]+), 630 ([MH]); (+)-HRESI-MS: m/z 654.3609
(calc: 654.3609 for C39H53NO6Na);
1H NMR: d at 0.86 (s,
6H, CH3-28, 24), 0.97 (s, 3H, CH3-23), 1.18 (s, 3H, CH3-27),
1.23 (s, 6H, CH3-25, 29), 1.36 (s, 3H, CH3-26), 2.04 (s, 3H,
CH3-32), 2.33 (s, 1H, CH-9), 2.65 (d, 1H, CH-1 eq), 4.49
(dd, 1H, CH-3), 5.94 (1H, s, CH-12), 6.60 (s, 1H, NH), 7.06
(t, 1H, CH-40), 7.51(t, 1H, CH-50), 8.03(d, 1H, CH-60), 8.74(d, 1H, CH-30), 11.34 (br-s, 1H, Ar–COOH); 13C NMR: d at
38.77 (C-1), 23.51 (C-2), 80.51 (C-3), 38.00 (C-4), 55.18 (C-
5), 17.46 (C-6), 32.17 (C-7), 45.54 (C-8), 60.67 (C-9), 36.88
(C-10), 202.46 (C-11), 128.79 (C-12), 170.69 (C-13), 45.54 (C-
14), 26.18 (C-15), 25.50 (C-16), 31.92 (C-17), 46.52 (C-18),
43.87 (C-19), 43.87 (C-20), 30.38 (C-21), 37.10 (C-22), 28.05
(C-23), 16.79 (C-24), 14. 11 (C-25), 18.48 (C-26), 22.68 (C-
27), 29.35 (C-28), 29.69 (C-29), 175.97 (C-30), 170.99 (C-31),
21.30 (C-32), 141.82 (C-10), 115.67 (C-20), 131.23 (C-30),
122.52 (C-40), 134.48 (C-50), 120.54 (C-60), 164.54 (Ar-COOH).
3.2.10. N-(5-Methyl isoxazol 3-yl)-3b-acetyl-11-oxoolean-12-
en-18b-H-30-amide (4h)
M.p 255–257 C; yield 71%; (+)-ESI-MS: m/z (%) 615
([M+ Na]+), 591([MH]); (+)-HRESI-MS: m/z 615.3767
(calc: 615.3768 for C36H52N2O5Na);
1H NMR: d at 0.77 (s,
3H, CH3-28), 0.84 (s, 6H, CH3-24, 23), 1.08 (s, 3H, CH3-27),
1.12 (s, 3H, CH3-25), 1.21 (s, 3H, CH3-29), 1.35 (s, 3H,
CH3-26), 2.02 (s, 3H, CH3-32), 2.32 (s, 1H, CH-9), 2,36 (s,
3H, CH3-33), 2.78 (d, 1H, CH-1 eq), 4.48 (dd, 1H, CH-3),
5.68 (s, 1H, CH-12), 6.74 (s, 1H, CH-4’), 9.06 (s, 1H, NH);
13C NMR: d at 38.77 (C-1), 23.52 (C-2), 80.59 (C-3), 38.00
(C-4), 55.00 (C-5), 17.34 (C-6), 32.68 (C-7), 45.32 (C-8),
61.67 (C-9), 36.88 (C-10), 199.75 (C-11), 128.65 (C-12),
169.70 (C-13), 44.58 (C-14), 26.38 (C-15), 26.35 (C-16), 31.68
(C-17), 47.66 (C-18), 41.06 (C-19), 43.13 (C-20), 32.23 (C-
21), 37.44 (C-22), 28.01 (C-23), 16.64 (C-24), 16. 34 (C-25),
18.63 (C-26), 23.33 (C-27), 28.34 (C-28), 29.64 (C-29), 174.60
(C-30), 170.97 (C-31), 21.26 (C-32), 158.54 (C-30), 96.92 (C-
40), 168.57 (C-50), 12.57 (CH3-isoxazole).
3.2.11. N-[2-(4-sulfamoylphenyl)ethyl]-3b-acetyl-11-oxoolean-
12-en-18b-H-30-amide (4i)
M.p 153–155 C; yield 78%; (+)-ESI-MS: m/z (%) 717
([M+ Na]+), 1412 ([2 M+Na]+); (+)-HRESI-MS: m/z
717.3913 (calc: 717.3908 for C40H58N2O6SNa);
1H NMR: d
at 0.81 (s, 3H, CH3-28), 0.83 (s, 6H, CH3-23, 24), 1.04 (s,
3H, CH3-27), 1.09 (s, 3H, CH3-25), 1.10 (s, 3H, CH3-29),
1.27 (s, 3H, CH3-26), 2.02 (s, 3H, CH3-32), 2.26 (s, 1H, CH-
9), 2.65 (d, 1H, CH-1 eq), 2.9 (m, 2H, CH2-34), 3.76 (m, 2H,
CH2-33), 4.45 (dd, 1H, CH-3), 5.02 (s, 1H, CH-12), 5.82 (t,
1H, NH), 7.29 (d, 2H, CH-30, 50), 7.81 (d, 2H, CH-20, 60),
J20,30 = J50, 60 = 6 Hz;
13C NMR: d at 38.57 (C-1), 23.46 (C-
2), 80.52 (C-3), 37.98 (C-4), 54.95 (C-5), 17.27 (C-6), 32.60
(C-7), 45.49 (C-8), 61.77 (C-9), 36.94 (C-10), 201.24 (C-11),
127.99 (C-12), 170.55 (C-13), 43.76 (C-14), 26.33 (C-15),
26.23 (C-16), 31.90 (C-17), 48.09 (C-18), 41.53 (C-19), 43.27
(C-20), 31.55 (C-21), 37.52 (C-22), 27.97 (C-23), 16.61 (C-
24), 16. 37 (C-25), 18.63 (C-26), 23.19 (C-27), 28.51 (C-28),
29.53 (C-29), 176.00 (C-30), 171.07 (C-31), 21.27 (C-32),
40.59 (C-33), 35.51 (C-34), 144.33 (C-10), 129.50 (C-20),
126.79 (C-30), 140.94 (C-40), 126.79 (C-50), 129.50 (C-60).
3.2.12. N-(morpholyl)-3b-acetyl-11-oxoolean-12-en-18b-H-30-
amide (4j)
M.p 169–171 C; yield 75%; (+)-ESI MS: m/z (%) 604
([M+ Na]+, 100), 1185 ([2 M+Na]+, 40), 580 ([MH];
(+)-HRESI MS: m/z 582.4151 (calc: 582.4153 for
C36H56NO5), 604.3973 (calc: 604.3972 for C36H55NO5Na);
1H NMR: d at 0.79 (s, 3H, CH3-28), 0.82 (s, 6H, CH3-23,
24), 1.07 (s, 3H, CH3-27), 1.10 (s, 3H, CH3-25), 1.19 (s, 3H,
Synthesis and biological activity of new 18b-glycyrrhetinic acid derivatives 397CH3-29), 1.31 (s, 3H, CH3-26), 2.02 (s, 3H, CH3-32), 2.17 (m,
4H, CH2-2
0, 60), 2.31 (s, 1H, CH-9), 2.77 (d, 1H, CH-1 eq), 2.98
(m, 4H, CH2-3
0, 50), 4.47 (dd, 1H, CH-3), 5.63 (s, 1H, CH-12);
13C NMR: d at 38.45 (C-1), 23.23 (C-2), 80.25 (C-3), 37.69 (C-
4), 54.63 (C-5), 17.04 (C-6), 32.70 (C-7), 45.64 (C-8), 61.34 (C-
9), 36.61 (C-10), 199.64 (C-11), 128.10 (C-12), 169.42 (C-13),
44.96 (C-14), 26.37 (C-15), 26.07 (C-16), 32.38 (C-17), 47.81
(C-18), 42.98 (C-19), 43.48 (C-20), 31.43 (C-21), 37.38 (C-
22), 26.59 (C-23), 16.73 (C-24), 16. 09 (C-25), 18.36 (C-26),
22.76 (C-27), 27.72 (C-28), 28.11 (C-29), 173.76 (C-30),
170.62 (C-31), 20.98 (C-32), 22.43 (C-20), 50.83 (C-30), 50.83
(C-50), 22.43 (C-60).
3.2.13. (3,5-Dimethylphenyl)-3b-acetyl-11-oxoolean-12-en-18b-
H-30-oate (5a)
M.p 207–209 C; yield 69%; (+)-ESI-MS: m/z (%)
617([M +H]+), 639 ([M +Na]+), 1455 ([2 M+ Na]+);
(+)-HRESI-MS: m/z 617.4171 (calc: 617.4201 for
C40H57O5);
1H NMR: d at 0.87 (s, 9H, CH3-28, 23, 24), 1.15
(s, 6H, CH3-27, 25), 1.25 (s, 3H, CH3-25), 1.33 (s, 3H, CH3-29),
1.39 (s, 3H, CH3-26), 2.05 (s, 3H, CH3-32), 2.31 (s, 1H, CH-
9), 2.32 (s, 6H, two CH3–Ar), 2.79 (d, 1H, CH-1 eq), 4.52
(dd, 1H, CH-3), 5.69 (s, 1H, CH-12), 6.64 (s, 2H, CH-2’, 6’),
6.86 (s, 1H, CH-40); 13C NMR: d at 39.81 (C-1), 23.99 (C-2),
81.05 (C-3), 38.48 (C-4), 55.44 (C-5), 17.81 (C-6), 33.14 (C-
7), 45.85 (C-8), 62.16 (C-9), 37.34 (C-10), 199.92 (C-11),
128.00 (C-12), 169.51 (C-13), 44.66 (C-14), 26.86 (C-15),
26.86 (C-16), 31.58 (C-17), 48.85 (C-18), 41.49 (C-19), 43.29
(C-20), 30.61 (C-21), 38.17 (C-22), 28.48 (C-23), 17.12 (C-
24), 16. 15 (C-25), 19.10 (C-26), 23.80 (C-27), 28.61 (C-28),
29.03 (C-29), 177.80 (C-30), 171.76 (C-31), 21.79 (C-32),
150.65 (C-33), 119.40 (C-34), 139.78 (C-10), 129.07 (C-20),
139.78 (C-30), 119.40 (C-40), 39.81 (C-50), 32.99 (C-60), 21.69
(Two CH3–Ar).
3.2.14. (4-methylphenyl)-3b-acetyl-11-oxoolean-12-en-18b-H-
30-oate (5b)
M.p 221–223 C; yield 71%; (+)-ESI-MS: m/z (%) 625
([M +Na]+), 601 ([MH]); (+)-HRESI-MS: m/z 603.4043
(calc: 603.4044 for C39H55O5);
1H NMR: d at 0.82 (s, 3H,
CH3-28), 0.85 (s, 6H, CH3-23, 24), 1.14 (s, 3H, CH3-27), 1.15
(s, 3H, CH3-25), 1.33 (s, 3H, CH3-29), 1.37 (s, 3H, CH3-26),
2.02 (s, 3H, CH3-32), 2.35 (s, 3H, CH3-Ar), 2.37 (s, 1H, CH-
9), 2.79 (d, 1H, CH-1 eq), 4.53 (dd, 1H, CH-3), 5.63 (s, 1H,
CH-12), 6.9 (d, 2H, CH-30, 50), 7.17 (d, 2H, CH-20, 60), J20,
30 = J50, 60 = 6 Hz;
13C NMR: d at 38.78 (C-1), 23.61 (C-2),
80.56 (C-3), 38.06 (C-4), 55.02 (C-5), 17.43 (C-6), 32.74 (C-
7), 45.40 (C-8), 61.71 (C-9), 36.96 (C-10), 199.76 (C-11),
128.50 (C-12), 168.74 (C-13), 44.21 (C-14), 26.50 (C-15),
26.47 (C-16), 31.95 (C-17), 48.46 (C-18), 41.13 (C-19), 43.23
(C-20), 31.20 (C-21), 37.76 (C-22), 28.08 (C-23), 16.73 (C-
24), 16. 44 (C-25), 18.74 (C-26), 23.39 (C-27), 28.14 (C-28),
29.62 (C-29), 175.03 (C-30), 170.71 (C-31), 21.34 (C-32),
148.39 (C-33), 120.98 (C-34), 129.81 (C-10), 135.26 (C-20),
129.81 (C-30), 120.98 (C-40), 38.78 (C-50), 23.61 (C-60), 20.90
(CH3- Ar).
3.2.15. (4-ethyl carboxyphenyl)-3b-acetyl-11-oxoolean-12-en-
18b-H-30-oate (5c)
M.p 209–211 C; yield 76%; (+)-ESI-MS: m/z (%) 683
([M +Na]+); (+)-HRESI-MS: m/z 683.3919 (calc: 683.3918for C41H56O7Na);
1H NMR: d at 0.85 (s, 9H, CH3-28, 23,
24), 1.12 (s, 6H, CH3-27, 25), 1.36 (s, 9H, CH3-26, 29), 1.42
(t, 3H, O–CH2–CH3), 2.02 (s, 3H, CH3-32), 2.34 (s, 1H, CH-
9), 2.76 (d, 1H, CH-1 eq), 4.35 (q, 2H, O‚C–O–CH2), 4.49
(dd, 1H, CH-3), 5.65 (s, 1H, CH-12), 7.08 (d, 2H, CH-30, 50),
8.06 (d, 2H, CH-20, 60), J20, 30 = J50, 60 = 9 Hz;
13C NMR: d
at 38.72 (C-1), 23.52 (C-2), 80.56 (C-3), 38.02 (C-4), 54.98
(C-5), 17.34 (C-6), 32.67 (C-7), 45.38 (C-8), 61.72 (C-9),
36.90 (C-10), 200.02 (C-11), 128.64 (C-12), 168.74 (C-13),
44.41 (C-14), 26.39 (C-15), 26.39 (C-16), 31.93 (C-17), 48.45
(C-18), 40.97 (C-19), 43.18 (C-20), 31.08 (C-21), 37.72 (C-
22), 28.05 (C-23), 16.66 (C-24), 16. 38 (C-25), 18.64 (C-26),
23.36 (C-27), 28.05 (C-28), 28.57 (C-29), 174.61 (C-30),
171.04 (C-31), 21.32 (C-32), 154.40 (C-33), 121.43 (C-34),
131.14 (C-10), 134.67 (C-20), 131.14 (C-30), 121.43 (C-40),
38.72 (C-50), 23.52 (C-60), 167.90 (O‚C–Ar), 61.08 (O–CH2),
14.31(CH2–CH3).3.2.16. (4-chlorophenyl)-3b-acetyl-11-oxoolean-12-en-18b-H-
30-oate (5d)
M.p 241–243 C; yield 78%; (+)-ESI-MS: m/z (%) 645
([M+ Na]+), 621 ([MH]); (+)-HRESI-MS: m/z
623.3496 (calc: 623.3497 for C38H52O5Cl);
1H NMR: d at
0.87 (s, 9H, CH3-28, 23, 24), 1.15 (s, 6H, CH3-27, 25), 1.33
(s, 3H, CH3-29), 1.38 (s, 3H, CH3-26), 2.04 (s, 3H, CH3-32),
2.36 (s, 1H, CH-9), 2.78 (d, 1H, CH-1 eq), 4.51 (dd, 1H,
CH-3), 5.66 (s, 1H, CH-12), 7.02 (d, 2H, CH-20, 60), 7.34
(d, 2H, CH-30, 50),J20, 30 = J50, 60 = 9 Hz;
13C NMR: d at
38.71 (C-1), 23.51 (C-2), 80.55 (C-3), 38.00 (C-4), 54.95 (C-
5), 17.32 (C-6), 32.65 (C-7), 45.37 (C-8), 61.70 (C-9), 36.88
(C-10), 200.04 (C-11), 128.61 (C-12), 168.78 (C-13), 44.28
(C-14), 26.36 (C-15), 26.36 (C-16), 31.90 (C-17), 48.47 (C-
18), 40.97 (C-19), 43.16 (C-20), 31.06 (C-21), 37.68 (C-22),
28.02 (C-23), 16.64 (C-24), 16. 37 (C-25), 18.62 (C-26),
23.33 (C-27), 28.02 (C-28), 28.55 (C-29), 174.88 (C-30),
171.03 (C-31), 21.30 (C-32), 149.50 (C-33), 122.81 (C-34),
129.49 (C-10), 131.10 (C-20), 129.49 (C-30), 122.81 (C-40),
38.71 (C-50), 23.51 (C-60).3.2.17. (4-bromophenyl)-3b-acetyl-11-oxoolean-12-en-18b-H-
30-oate (5e)
M.p 243–245 C; yield 79%; (+)-ESI-MS: m/z (%) 667
([M+ H]+); (+)-HRESI-MS: m/z 667.2989 (calc: 667.2992
for C38H52O5Br).
1H NMR: d at 0.87 (s, 9H, CH3-28, 23,
24), 1.15 (s, 6H, CH3-27, 25), 1.33 (s, 3H, CH3-29), 1.36
(s, 3H, CH3-26), 2.05 (s, 3H, CH3-32), 2.36 (s, 1H, CH-9),
2.78 (d, 1H, CH-1 eq), 4.52 (dd, 1H, CH-3), 5.66 (s, 1H,
CH-12), 6.93 (d, 2H, CH-20, 60), 7.49 (d, 2H, CH-30, 50),
J20, 30 = J50, 60 = 9 Hz;
13C NMR: d at 38.71 (C-1), 23.52
(C-2), 80.00 (C-3), 38.00 (C-4), 54.96 (C-5), 17.32 (C-6),
32.65 (C-7), 45.37 (C-8), 61.70 (C-9), 36.87 (C-10), 200.03
(C-11), 128.62 (C-12), 168.76 (C-13), 44.30 (C-14), 26.38
(C-15), 26.38 (C-16), 31.90 (C-17), 48.46 (C-18), 40.96 (C-
19), 43.16 (C-20), 31.06 (C-21), 37.68 (C-22), 28.02 (C-23),
16.65 (C-24), 16. 37 (C-25), 18.63 (C-26), 23.33 (C-27),
28.02 (C-28), 28.55 (C-29), 174.62 (C-30), 171.03 (C-31),
21.31 (C-32), 149.78 (C-33), 123.25 (C-34), 132.47 (C-10),
119.90 (C-20), 132.47 (C-30), 123.25 (C-40), 38.71 (C-50),
23.52 (C-60).
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ketoolean-12-en-18-bH-30-amide (6)
To a solution of 4g (500 mg, 0.75 mmol) in MeOH (50 ml) was
added KOH (490 mg). After being reﬂuxed for 3 h, the reac-
tion mixture was neutralized with 2 N HCl, the formed precip-
itate was ﬁltered under vacuum, washed with water and dried
to give a yellowish residue. It was crystallized several times
from methanol to give rise to 360 mg of compound 6.
m.p 279–280 C; yield: 77%; 1H NMR: d at0.78 (s, 3H,
CH3-28), 0.86 (s, 3H, CH3-24), 0.89 (s, 3H, CH3-23), 1.08 (s,
3H, CH3-27), 1.12 (s, 3H, CH3-25), 1.25 (s, 3H, CH3-29),
1.39 (s, 3H, CH3-26), 2.40 (s, 1H, CH-9), 2.75 (d, 1H, CH-
1 eq), 4.52 (dd, 1H, CH-3), 5.97 (s, 1H, CH-12), 7.09(t, 1H,
CH-40), 7.56(t, 1H, CH-5’), 8.10(d, 1H, CH-60), 8.76 (d, 1H,
CH-30), 11.63 (br-s, 1H, Ar-COOH).
3.2.19. General procedures for the preparation of compounds 7
and 8
To a solution of 6 (150 mg, 0.26 mmol) in dry pyridine (10 ml),
was added succinic anhydride (400 mg, 4 mmol) for the prepa-
ration of compound 7 or phthalic anhydride (600 mg, 4 mmol)
for the preparation of compound 8, in presence of 4A molec-
ular sieve. The mixture was reﬂuxed for 8 h, neutralized by
hydrochloric acid. The formed precipitate was ﬁltered under
vacuum, washed with water and dried. Each of the residues
was puriﬁed on silica gel column chromatography.
3.2.20. N-(2-carboxyphenyl)-3b-O-carboxypropanoyloxy-11-
oxoolean-18b-H-30-amide (7)
m.p 169–170 C; yield:59%; (+)-ESI-MS: m/z (%) 688 ([M-
H]-, 100); (+)-HRESI-MS: m/z 688.3851 (calc: 688.3855 for
C41H54NO8).
1H NMR: d at 0.77 (s, 3H, CH3-28), 0.83 (s,
3H, CH3-24), 0.86 (s, 3H, CH3-23), 1.08 (s, 3H, CH3-27),
1.11 (s, 3H, CH3-25), 1.23 (s, 3H, CH3-29), 1.39 (s, 3H,
CH3-26), 2.39 (s, 1H, CH-9), 2.66 (t, 4H, CH2-32, 33),2.75
(d, 1H, CH-1 eq), 4.52 (dd, 1H, CH-3), 5.97 (s, 1H, CH-12),
7.08(t, 1H, CH-40), 7.54(t, 1H, CH-50), 8.09(d, 1H, CH-60),
8.78 (d, 1H, CH-3’), 11.63 (br-s, 1H, Ar–COOH); 13C NMR:
d at 38.87 (C-1), 23.45 (C-2), 81.04 (C-3), 38.05 (C-4), 54.99
(C-5), 17.30 (C-6), 32.63 (C-7), 45.75 (C-8), 61.71 (C-9),
37.08 (C-10), 201.80 (C-11), 128.79 (C-12), 170.72 (C-13),
45.52 (C-14), 26.45 (C-15), 26.35 (C-16), 31.89 (C-17), 47.95
(C-18), 41.04 (C-19), 43.40 (C-20), 31.02 (C-21), 37.64 (C-
22), 28.01 (C-23), 16.70 (C-24), 16. 43 (C-25), 18.72 (C-26),
23.35 (C-27), 28.50 (C-28), 29.03 (C-29), 177.12 (C-30),
175.25 (C-31), 29.69 (C-32), 29.69 (C-33), 172.14 (C-34),
142.23 (C-10), 114.95 (C-20), 131.54 (C-30), 122.46 (C-40),
134.90 (C-50), 120.54 (C-60), 171.82 (Ar–COOH).
3.2.21. N-(2-carboxyphenyl)-3b-O-phthaloyl-11-oxoolean-18b-
H-30-amide (8)
m.p 177–178 C; yield:62%; (+)-ESI-MS: m/z (%) 760
([M+ Na]+), 736 ([MH]); (+)-HRESI-MS: m/z 760.3813
(calc: 760.3820 for C45H55NO8Na).
1H NMR: d at 0.77 (s,
3H, CH3-28), 0.90 (s, 3H, CH3-24), 0.96 (s, 3H, CH3-23),
1.09 (s, 3H, CH3-27), 1.10 (s, 3H, CH3-25), 1.28 (s, 3H,
CH3-29), 1.41 (s, 3H, CH3-26), 2.43 (s, 1H, CH-9), 2.78 (d,
1H, CH-1 eq), 4.79 (dd, 1H, CH-3), 6.13 (s, 1H, CH-12),
7.06 (t, 1H, CH-400), 7.52 (m, 3H, CH-50, 40, 50), 7.67 (m, 1H,
CH-60),7.86 (s, 1H,CH-30 0), 8.03 (d, 1H, 60), 8.76 (d, 1H, 30).3.2.22. Preparation of N-[2-(N-P-tolyl-benzamide)]-phenyl-
3b-acetyl-11-oxoolean-12-en-18b-H-30-amide (9)
Compound 4g (100 mg, 0.15 mmol) was dissolved in 10 ml dry
dichloromethane and triethylamine (25 ll, 0.15 mmol) was
added. After stirring for 5 min, 0.02 ml of ethylchloroformate
was added, followed by stirring for one hour, then 17 mg
(0.15 mmol) of p-toluidine was added. Stirring is continued over
night. Water (10 ml) was added and the organic layer was sepa-
rated. It was washed at ﬁrst with 2 N HCl followed with water,
dried over anhydrous sodium sulfate and the solvent distilled
off. The residue was puriﬁed on silica gel column
chromatography.
m.p 149–150 C; yield: 67%; (+)-ESI-MS: m/z (%) 643
([M+ Na]+, 100), 719 ([MH]); (+)-HRESI-MS: m/z
743.4382 (calc: 743.4394 for C46H60N2O5Na).
1H NMR: d
at 0.77 (s, 3H, CH3-28), 0.85 (s, 6H, CH3-23, 24), 1.08 (s,
3H, CH3-27), 1.13 (s, 3H, CH3-25), 1.20 (s, 3H, CH3-29),
1.37 (s, 3H, CH3-26) 2.03 (s, 3H, CH3-32), 2.29 (s, 3H,
CH3-Ar), 2.34 (s, 1H, CH-9), 2.76 (d, 1H, CH-1 eq), 4.50
(dd, 1H, CH-3), 5.79 (1H, s, CH-12), 7.07(t, 1H, CH-40),
7.12 (d, 2H, CH-300, 500), 7.42 (d, 2H, CH-200, 600), 7.51 (t,
1H, CH-50), 7.62 (d, 1H, CH-60),8.15 (s, 1H, NH), 8.57 (d,
1H, CH-30), 11.26 (s, 1H, NH).
3.2.23. General procedures for the preparation of compounds 11–
13
A mixture of 100 mg (0.19 mmol) of compound 10 and
0.8 mmol of the appropriate acid anhydride were boiled for
10 h in 2 ml dry pyridine, in presence of 200 mg 4A molecular
sieve, without access of water. The reaction mixture was di-
luted with 2 ml of acetone, acidiﬁed with hydrochloric acid
to pH  3–4. The residue was ﬁltered under vacuum, washed
with hot water, dried over anhydrous sodium sulfate and the
solvent distilled off. Each residue was puriﬁed on silica gel col-
umn chromatography. It was eluted with hexane–ethyl acetate
system, (step gradient mode, 8:2–7:3 v/v).3.2.24. 3-O-b-carboxypropionyl-11-oxoolean-12-en-18b-H-20b-
O-methyl ester (11)
m.p 262–265 C [lit. 262–264 C (Kondratenko et al., 2001)];
yield: 68%;(+)-ESI-MS: m/z (%) 607 ([M+ Na]+), 583
([M-H]-); (+)-HRESI-MS: m/z 583.3646 (calc: 583.3640 for
C35H51O7).
1H NMR: d at 0.78 (s, 3H, CH3-28), 0.85 (s, 3H,
CH3-24, 23), 1.10 (s, 3H, CH3-27), 1.12 (s, 3H, CH3-25),
1.23 (s, 3H, CH3-29), 1.34 (s, 3H, CH3-26), 2.33 (s, 1H,
CH-9), 2.63 (m, 4H, CH2-32, 33), 2.77 (d, 1H, CH-1 eq),
3.66 (s, 3H, CH3-35), 4.52 (dd, 1H, CH-3),5.64 (s, 1H, CH-
12).3.2.25. 3-O-b-phthaloyl-11-oxoolean-12-en-18b-H-20b-O-
methyl ester (12)
m.p 156–158 C(lit. 154–157 C (Kondratenko et al., 2001);
yield: 71%;(+)-ESI-MS: m/z (%) 655 ([M+ Na]+), 631
([MH]); (+)-HRESI-MS: m/z 631.3642 (calc: 631.3640
for C39H51O7).
1H NMR: d at 0.78 (s, 3H, CH3-28), 0.92
(s, 3H, CH3-24), 0.96 (s, 3H, CH3-23), 1.11 (s, 3H,
CH3-27), 1.13 (s, 3H, CH3-25), 1.23 (s, 3H, CH3-29), 1.36
(s, 3H, CH3-26), 2.37 (s, 1H, CH-9), 2.85 (d, 1H, CH-1 eq),
3.67 (s, 3H, CH3-32), 4.79 (dd, 1H, CH-3), 5.67 (s, 1H,
Synthesis and biological activity of new 18b-glycyrrhetinic acid derivatives 399CH-12), 7.56 (m, 2H, CH-40, 50), 7.75 (m, 1H, CH-60), 7.93
(m, 1H, CH-30).
3.2.26. 3-O-b-Carboxy-trans-propenoyl-11-oxoolean-12-en-18b-
H-20b-O-methyl ester (13)
m.p 209–211 C; yield: 45%;(+)-ESI-MS: m/z (%) 605
([M +Na]+), 581 ([M-H]-); (+)-HRESI-MS: m/z 581.3485
(calc: 581.3484 for C35H49NO7).
1H NMR: d at 0.78 (s, 3H,
CH3-28), 0.87 (s, 3H, CH3-24), 0.90 (s, 3H, CH3-23), 1.11 (s,
3H, CH3-27), 1.13 (s, 3H, CH3-25), 1.23 (s, 3H, CH3-29),
1.35 (s, 3H, CH3-26), 2.35 (s, 1H, CH-9), 2.80 (d, 1H, CH-
1 eq), 3.67 (s, 3H, CH3-35), 4.60 (dd, 1H, CH-3), 5.65 (s, 1H,
CH-12), 6.82 (s, 2H, CH-32, 33).3.3. Anti-inﬂammatory testing
Rats used in the biological testing of glycyrrhetinic acid and its
derivatives were obtained from The Animal House Colony of
the National Research Centre (NRC), Egypt. Seventy mature
Wistar rats of both sexes, weighing 150–200 g were used. All
animals were housed in hygienic cages in well ventilated rooms
with exhaust fans; received standard pellet diet and water were
provided ad libitum. The study was performed at the Pharma-
cology Research Unit- NRC and was approved by the Ethics
Committee of The National Research Centre and in accordance
with the recommendations of the proper care and use of labo-
ratory animals (published by the National Academy of Science,
National Academy Press, Washington, D.C.).
The anti-inﬂammatory test was performed according to the
method of (Winter et al., 1962). Paw edema was induced in rats
by subcutaneous (s.c.) injection of 0.1 ml of 1% (w/v) caragee-
nan in distilled water in the sub-plantar region of their left hind
paws. A group of rats was left without any treatment but were
given a respective volume of the solvent (few drops of tween-
80 in distilled water), and was kept as a control group. Drugs
were administered orally at a dose of 100 mg/kg, onehour before
carageenan injection. Oral prednisolone (Hostacortin-H,
5 mg/kg) and indomethacin (Indocid, 20 mg/kg) were admin-
istered to two groups of rats as reference drugs. The paw volume
of each rat was measured using ﬂuid displacement method, uti-
lizing plethysmometer apparatus at 0–4 h of carageenan
injection.
Edema rate and inhibition rate of each group were calcu-
lated at the previously mentioned time intervals as follows:
Edema rateð%Þ ¼ Vt Vo=VoInhibition rateð%Þ
¼ Ec Et=Ec ð1Þ
where:
Vo is the volume before carageenan injection (ml); Vt is the
volume at t hour after carageenan injection (ml);
Ec is the edema rate of the control group; Et is the edema
rate of treated group.
The anti-inﬂammatory potencies of glycyrrhetinic acid and
its derivatives were calculated by comparing their inhibition
rate at different time intervals; with those obtained from ani-
mals receiving either prednisolone or indomethacin, respec-
tively, as standard anti-inﬂammatory drugs. Statistical
analysis of the results, was done using analytical software
named SPSS statistics 17.0, Release (Aug. 23, 2008), Chicago,
USA. (See Tables 1 and 2).Acknowledgments
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